Skip to main content
Erschienen in: European Radiology 8/2012

01.08.2012 | Breast

Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes

verfasst von: Ji Hyun Youk, Eun Ju Son, Jin Chung, Jeong-Ah Kim, Eun-kyung Kim

Erschienen in: European Radiology | Ausgabe 8/2012

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To determine the MRI features of triple-negative invasive breast cancer (TNBC) on dynamic contrast-enhanced MR imaging (DCE-MRI) and diffusion-weighted MR imaging (DWI) in comparison with ER-positive/HER2-negative (ER+) and HER2-positive cancer (HER2+).

Methods

A total of 271 invasive cancers in 269 patients undergoing preoperative MRI and surgery were included. Two radiologists retrospectively assessed morphological and kinetic characteristics on DCE-MRI and tumour detectability on DWI. Apparent diffusion coefficient (ADC) values of lesions were measured. Clinical and MRI features of the three subtypes were compared.

Results

Compared with ER+ (n = 119) and HER2+ (n = 94), larger size, round/oval mass shape, smooth mass margin, and rim enhancement on DCE-MRI were significantly associated with TNBC (n = 58; P < 0.0001). On DWI, mean ADC value (×10−3 mm2/s) of TNBC (1.03) was higher than the mean ADC values for ER+ and HER2+ (0.89 and 0.84; P < 0.0001). There was no difference in tumour detectability (P = 0.099). Tumour size (P = 0.009), mass margin (smooth, P < 0.0001; irregular, P = 0.020), and ADC values (P = 0.002) on DCE-MRI and DWI were independent features of TNBC.

Conclusions

In addition to the morphological features, higher ADC values on DWI were independently associated with TNBC and could be useful in differentiating TNBC from ER+ and HER2+.

Key Points

Triple-negative breast cancers (TNBC) lack oestrogen/progesterone receptors and HER2 expression/amplification.
TNBCs are larger, better defined and more necrotic than conventional cancers.
On MRI, necrosis yields high T2-weighted signal intensity and ADCs.
High ADC values can be useful in diagnosing TNBC.
Literatur
1.
Zurück zum Zitat Yamamoto Y, Iwase H (2010) Clinicopathological features and treatment strategy for triple-negative breast cancer. Int J Clin Oncol 15:341–351PubMedCrossRef Yamamoto Y, Iwase H (2010) Clinicopathological features and treatment strategy for triple-negative breast cancer. Int J Clin Oncol 15:341–351PubMedCrossRef
2.
Zurück zum Zitat de Ronde JJ, Hannemann J, Halfwerk H et al (2010) Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat 119:119–126PubMedCrossRef de Ronde JJ, Hannemann J, Halfwerk H et al (2010) Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat 119:119–126PubMedCrossRef
3.
Zurück zum Zitat Denley H, Pinder SE, Elston CW, Lee AH, Ellis IO (2001) Preoperative assessment of prognostic factors in breast cancer. J Clin Pathol 54:20–24PubMedCrossRef Denley H, Pinder SE, Elston CW, Lee AH, Ellis IO (2001) Preoperative assessment of prognostic factors in breast cancer. J Clin Pathol 54:20–24PubMedCrossRef
4.
Zurück zum Zitat Montagna E, Bagnardi V, Rotmensz N et al (2011) Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation. Breast Cancer Res Treat 129:867–875PubMedCrossRef Montagna E, Bagnardi V, Rotmensz N et al (2011) Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation. Breast Cancer Res Treat 129:867–875PubMedCrossRef
5.
Zurück zum Zitat Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869–10874PubMedCrossRef Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869–10874PubMedCrossRef
6.
Zurück zum Zitat Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMedCrossRef Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMedCrossRef
7.
Zurück zum Zitat Li SP, Padhani AR, Taylor NJ et al (2011) Vascular characterisation of triple negative breast carcinomas using dynamic MRI. Eur Radiol 21:1364–1373PubMedCrossRef Li SP, Padhani AR, Taylor NJ et al (2011) Vascular characterisation of triple negative breast carcinomas using dynamic MRI. Eur Radiol 21:1364–1373PubMedCrossRef
8.
Zurück zum Zitat van de Vijver MJ, He YD, van’t Veer LJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009PubMedCrossRef van de Vijver MJ, He YD, van’t Veer LJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009PubMedCrossRef
9.
Zurück zum Zitat Desmedt C, Haibe-Kains B, Wirapati P et al (2008) Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14:5158–5165PubMedCrossRef Desmedt C, Haibe-Kains B, Wirapati P et al (2008) Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14:5158–5165PubMedCrossRef
10.
Zurück zum Zitat Sanchez-Munoz A, Garcia-Tapiador AM, Martinez-Ortega E et al (2008) Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Clin Transl Oncol 10:646–653PubMedCrossRef Sanchez-Munoz A, Garcia-Tapiador AM, Martinez-Ortega E et al (2008) Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Clin Transl Oncol 10:646–653PubMedCrossRef
11.
Zurück zum Zitat Elsawaf Z, Sinn HP (2011) Triple-negative breast cancer: clinical and histological correlations. Breast Care (Basel) 6:273–278 Elsawaf Z, Sinn HP (2011) Triple-negative breast cancer: clinical and histological correlations. Breast Care (Basel) 6:273–278
12.
Zurück zum Zitat Ko ES, Lee BH, Kim HA, Noh WC, Kim MS, Lee SA (2010) Triple-negative breast cancer: correlation between imaging and pathological findings. Eur Radiol 20:1111–1117PubMedCrossRef Ko ES, Lee BH, Kim HA, Noh WC, Kim MS, Lee SA (2010) Triple-negative breast cancer: correlation between imaging and pathological findings. Eur Radiol 20:1111–1117PubMedCrossRef
13.
Zurück zum Zitat Dogan BE, Gonzalez-Angulo AM, Gilcrease M, Dryden MJ, Yang WT (2010) Multimodality imaging of triple receptor-negative tumors with mammography, ultrasound, and MRI. AJR Am J Roentgenol 194:1160–1166PubMedCrossRef Dogan BE, Gonzalez-Angulo AM, Gilcrease M, Dryden MJ, Yang WT (2010) Multimodality imaging of triple receptor-negative tumors with mammography, ultrasound, and MRI. AJR Am J Roentgenol 194:1160–1166PubMedCrossRef
14.
Zurück zum Zitat Yang WT, Dryden M, Broglio K et al (2008) Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women. Breast Cancer Res Treat 111:405–410PubMedCrossRef Yang WT, Dryden M, Broglio K et al (2008) Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women. Breast Cancer Res Treat 111:405–410PubMedCrossRef
15.
Zurück zum Zitat Whitman GJ, Albarracin CT, Gonzalez-Angulo AM (2011) Triple-negative breast cancer: what the radiologist needs to know. Semin Roentgenol 46:26–39PubMedCrossRef Whitman GJ, Albarracin CT, Gonzalez-Angulo AM (2011) Triple-negative breast cancer: what the radiologist needs to know. Semin Roentgenol 46:26–39PubMedCrossRef
16.
Zurück zum Zitat Chen JH, Agrawal G, Feig B et al (2007) Triple-negative breast cancer: MRI features in 29 patients. Ann Oncol 18:2042–2043PubMedCrossRef Chen JH, Agrawal G, Feig B et al (2007) Triple-negative breast cancer: MRI features in 29 patients. Ann Oncol 18:2042–2043PubMedCrossRef
17.
Zurück zum Zitat Uematsu T, Kasami M, Yuen S (2009) Triple-negative breast cancer: correlation between MR imaging and pathologic findings. Radiology 250:638–647PubMedCrossRef Uematsu T, Kasami M, Yuen S (2009) Triple-negative breast cancer: correlation between MR imaging and pathologic findings. Radiology 250:638–647PubMedCrossRef
18.
Zurück zum Zitat Podo F, Buydens LM, Degani H et al (2010) Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol 4:209–229PubMedCrossRef Podo F, Buydens LM, Degani H et al (2010) Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol 4:209–229PubMedCrossRef
19.
Zurück zum Zitat Woodhams R, Kakita S, Hata H et al (2010) Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging – comparison with contrast-enhanced MR imaging and pathologic findings. Radiology 254:357–366PubMedCrossRef Woodhams R, Kakita S, Hata H et al (2010) Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging – comparison with contrast-enhanced MR imaging and pathologic findings. Radiology 254:357–366PubMedCrossRef
20.
Zurück zum Zitat Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155–168PubMed Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155–168PubMed
21.
Zurück zum Zitat Moeder CB, Giltnane JM, Harigopal M et al (2007) Quantitative justification of the change from 10 % to 30 % for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. J Clin Oncol 25:5418–5425PubMedCrossRef Moeder CB, Giltnane JM, Harigopal M et al (2007) Quantitative justification of the change from 10 % to 30 % for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. J Clin Oncol 25:5418–5425PubMedCrossRef
22.
Zurück zum Zitat American College of Radiology (2003) Breast imaging reporting and data system-magnetic resonance imaging. In: American College of Radiology (ed) Breast imaging reporting and data system, 4th edn. American College of Radiology, Reston, pp 1–114 American College of Radiology (2003) Breast imaging reporting and data system-magnetic resonance imaging. In: American College of Radiology (ed) Breast imaging reporting and data system, 4th edn. American College of Radiology, Reston, pp 1–114
23.
Zurück zum Zitat Kuhl CK, Mielcareck P, Klaschik S et al (1999) Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology 211:101–110PubMed Kuhl CK, Mielcareck P, Klaschik S et al (1999) Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology 211:101–110PubMed
24.
Zurück zum Zitat Koh DM, Collins DJ, Orton MR (2011) Intravoxel incoherent motion in body diffusion-weighted MRI: reality and challenges. AJR Am J Roentgenol 196:1351–1361PubMedCrossRef Koh DM, Collins DJ, Orton MR (2011) Intravoxel incoherent motion in body diffusion-weighted MRI: reality and challenges. AJR Am J Roentgenol 196:1351–1361PubMedCrossRef
25.
Zurück zum Zitat Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 295:2492–2502PubMedCrossRef Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 295:2492–2502PubMedCrossRef
26.
Zurück zum Zitat Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434PubMedCrossRef Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434PubMedCrossRef
27.
Zurück zum Zitat Anders C, Carey LA (2008) Understanding and treating triple-negative breast cancer. Oncology (Williston Park) 22:1233–1239 Anders C, Carey LA (2008) Understanding and treating triple-negative breast cancer. Oncology (Williston Park) 22:1233–1239
28.
Zurück zum Zitat Arnedos M, Nerurkar A, Osin P, A'Hern R, Smith IE, Dowsett M (2009) Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol 20:1948–1952PubMedCrossRef Arnedos M, Nerurkar A, Osin P, A'Hern R, Smith IE, Dowsett M (2009) Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol 20:1948–1952PubMedCrossRef
29.
Zurück zum Zitat Lorgis V, Algros MP, Villanueva C et al (2011) Discordance in early breast cancer for tumour grade, estrogen receptor, progesterone receptors and human epidermal receptor-2 status between core needle biopsy and surgical excisional primary tumour. Breast 20:284–287PubMedCrossRef Lorgis V, Algros MP, Villanueva C et al (2011) Discordance in early breast cancer for tumour grade, estrogen receptor, progesterone receptors and human epidermal receptor-2 status between core needle biopsy and surgical excisional primary tumour. Breast 20:284–287PubMedCrossRef
30.
Zurück zum Zitat Tamaki K, Sasano H, Ishida T et al (2010) Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER, PgR and HER2 status of breast cancer patients. Cancer Sci 101:2074–2079PubMedCrossRef Tamaki K, Sasano H, Ishida T et al (2010) Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER, PgR and HER2 status of breast cancer patients. Cancer Sci 101:2074–2079PubMedCrossRef
31.
Zurück zum Zitat Pal SK, Childs BH, Pegram M (2011) Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 125:627–636PubMedCrossRef Pal SK, Childs BH, Pegram M (2011) Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 125:627–636PubMedCrossRef
32.
Zurück zum Zitat Pereira FP, Martins G, de Oliveira C, Rde V (2011) Diffusion magnetic resonance imaging of the breast. Magn Reson Imaging Clin N Am 19:95–110PubMedCrossRef Pereira FP, Martins G, de Oliveira C, Rde V (2011) Diffusion magnetic resonance imaging of the breast. Magn Reson Imaging Clin N Am 19:95–110PubMedCrossRef
33.
Zurück zum Zitat Hamstra DA, Rehemtulla A, Ross BD (2007) Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 25:4104–4109PubMedCrossRef Hamstra DA, Rehemtulla A, Ross BD (2007) Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 25:4104–4109PubMedCrossRef
34.
Zurück zum Zitat Tsushima Y, Takahashi-Taketomi A, Endo K (2009) Magnetic resonance (MR) differential diagnosis of breast tumors using apparent diffusion coefficient (ADC) on 1.5-T. J Magn Reson Imaging 30:249–255PubMedCrossRef Tsushima Y, Takahashi-Taketomi A, Endo K (2009) Magnetic resonance (MR) differential diagnosis of breast tumors using apparent diffusion coefficient (ADC) on 1.5-T. J Magn Reson Imaging 30:249–255PubMedCrossRef
35.
Zurück zum Zitat Kim SH, Cha ES, Kim HS et al (2009) Diffusion-weighted imaging of breast cancer: correlation of the apparent diffusion coefficient value with prognostic factors. J Magn Reson Imaging 30:615–620PubMedCrossRef Kim SH, Cha ES, Kim HS et al (2009) Diffusion-weighted imaging of breast cancer: correlation of the apparent diffusion coefficient value with prognostic factors. J Magn Reson Imaging 30:615–620PubMedCrossRef
36.
Zurück zum Zitat Guo Y, Cai YQ, Cai ZL et al (2002) Differentiation of clinically benign and malignant breast lesions using diffusion-weighted imaging. J Magn Reson Imaging 16:172–178PubMedCrossRef Guo Y, Cai YQ, Cai ZL et al (2002) Differentiation of clinically benign and malignant breast lesions using diffusion-weighted imaging. J Magn Reson Imaging 16:172–178PubMedCrossRef
37.
Zurück zum Zitat Razek AA, Gaballa G, Denewer A, Nada N (2010) Invasive ductal carcinoma: correlation of apparent diffusion coefficient value with pathological prognostic factors. NMR Biomed 23:619–623PubMedCrossRef Razek AA, Gaballa G, Denewer A, Nada N (2010) Invasive ductal carcinoma: correlation of apparent diffusion coefficient value with pathological prognostic factors. NMR Biomed 23:619–623PubMedCrossRef
38.
Zurück zum Zitat Costantini M, Belli P, Rinaldi P et al (2010) Diffusion-weighted imaging in breast cancer: relationship between apparent diffusion coefficient and tumour aggressiveness. Clin Radiol 65:1005–1012PubMedCrossRef Costantini M, Belli P, Rinaldi P et al (2010) Diffusion-weighted imaging in breast cancer: relationship between apparent diffusion coefficient and tumour aggressiveness. Clin Radiol 65:1005–1012PubMedCrossRef
39.
Zurück zum Zitat Padhani AR, Liu G, Koh DM et al (2009) Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11:102–125PubMed Padhani AR, Liu G, Koh DM et al (2009) Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11:102–125PubMed
40.
Zurück zum Zitat Park SH, Moon WK, Cho N et al (2010) Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Radiology 257:56–63PubMedCrossRef Park SH, Moon WK, Cho N et al (2010) Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Radiology 257:56–63PubMedCrossRef
41.
Zurück zum Zitat Jeh SK, Kim SH, Kim HS et al (2011) Correlation of the apparent diffusion coefficient value and dynamic magnetic resonance imaging findings with prognostic factors in invasive ductal carcinoma. J Magn Reson Imaging 33:102–109PubMedCrossRef Jeh SK, Kim SH, Kim HS et al (2011) Correlation of the apparent diffusion coefficient value and dynamic magnetic resonance imaging findings with prognostic factors in invasive ductal carcinoma. J Magn Reson Imaging 33:102–109PubMedCrossRef
42.
Zurück zum Zitat Matsuoka A, Minato M, Harada M et al (2008) Comparison of 3.0- and 1.5-Tesla diffusion-weighted imaging in the visibility of breast cancer. Radiat Med 26:15–20PubMedCrossRef Matsuoka A, Minato M, Harada M et al (2008) Comparison of 3.0- and 1.5-Tesla diffusion-weighted imaging in the visibility of breast cancer. Radiat Med 26:15–20PubMedCrossRef
Metadaten
Titel
Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes
verfasst von
Ji Hyun Youk
Eun Ju Son
Jin Chung
Jeong-Ah Kim
Eun-kyung Kim
Publikationsdatum
01.08.2012
Verlag
Springer-Verlag
Erschienen in
European Radiology / Ausgabe 8/2012
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-012-2425-2

Weitere Artikel der Ausgabe 8/2012

European Radiology 8/2012 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.